Progress in Melanoma Histopathology and Diagnosis

Hematology/Oncology Clinics of North America

Volumn 23, Issue 3, 2009, Pages 467-480

  Piris, Adriano ^a   Mihm Jr , Martin C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Borderline lesions; Dermal mitoses; Histopathology; Melanoma; Prognosis

Indexed keywords

PROTEIN S 100; RNA POLYMERASE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CANCER SURGERY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; LYMPHADENECTOMY; MELANOMA; MITOSIS RATE; MOLECULAR BIOLOGY; MORPHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; ULCER;

HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MITOTIC INDEX; NEOPLASM INVASIVENESS; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; PRECANCEROUS CONDITIONS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS;

EID: 65649112134     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.03.012     Document Type: Review

References (51)

1. Clark Jr. W.H. A classification of malignant melanoma in man correlated with histogenesis and biological behaviour. In: Montagna W., and Hu F. (Eds). Advances in the biology of the skin vol. 8 (1967), Pergamon, New York 621-647
2. Mihm Jr. M.C., Clark Jr. W.H., and From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med 284 19 (1971) 1078-1082
3. Clark Jr. W.H., and Mihm Jr. M.C. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 55 1 (1969) 39-67
4. McGovern V.J. The classification of melanoma and its relationship with prognosis. Pathology 2 2 (1970) 85-98
5. Breslow A. Thickness, cross-sectional area, and depth of invasion in the prognosis of cutanenous melanoma. Ann Surg 172 (1970) 902-908
6. Clark Jr. W.H., Elder D.E., Guerry IV D., et al. Model predicting survival in stage I melanoma base on tumor progression. J Natl Cancer Inst 81 (1989) 1893-1904
7. Day Jr. C.L., Lew R.A., Mihm Jr. M.C., et al. A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg 195 1 (1982) 44-49
8. Day Jr. C.L., Mihm Jr. M.C., Lew R.A., et al. Prognostic factors for patients with clinical stage I melanoma of intermediated thickness (1.51-3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg 195 1 (1982) 35-43
9. Day Jr. C.L., Mihm Jr. M.C., Sober A.J., et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness. An appraisal of "thin" level lesions. Ann Surg 195 1 (1982) 30-34
10. Balch C.M., Murad T.M., Soong S.J., et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188 6 (1978) 732-742
11. Balch C.M., Buzaid A.C., Soon S.J., et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
12. Elder D.E., and Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 36 5 (2004) 428-434
13. Bastian B.C. Molecular genetics of melanocytic neoplasia: practical applications for diagnosis. Pathology 36 5 (2004) 458-461 Review
14. Bauer J., and Bastian B.C. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19 1 (2006) 40-49 Review
15. King R., Page R.N., Googe P.B., et al. Lentiginous melanoma: a histologic pattern of melanoma to be distinguished from lentiginous nevus. Mod Pathol 18 10 (2005) 1397-1401
16. Viros A., Fridlyand J., Bauer J., et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5 6 (2008) 0941-0952
17. Clark Jr. W.H., From L., Bernardino E.A., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29 3 (1969) 705-727
18. Clark Jr. W.H., Elder D.E., Guerry IV D., et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15 12 (1984) 1147-1165
19. Guerry IV D., Synnestvedt M., Elder D.E., et al. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100 3 (1993) 342S-345S
20. Elder D.E., Elenitsas R., Murphy G., et al. Benign pigmented lesions and malignant melanoma. In: Elder D.E. (Ed). Lever's histopathology of the skin. 10th edition (2009), Lippincot Williams, and Wilkins, (PA) 699-789
21. Walsh N., Crotty K., Palmer A., et al. Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing histopathologic criteria. Hum Pathol 29 10 (1998) 1105-1112
22. Urso C., Borgognoni L., Saieva C., et al. Sentinel lymph node biopsy in patients with "atypical Spitz tumors." A report on 12 cases. Hum Pathol 37 (2006) 816-823
23. Lohmann C.M., Coit D.G., Brady M.S., et al. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 26 (2002) 47-55
24. Zembowicz A., Carney J.A., and Mihm M.C. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 28 1 (2004) 31-40 Erratum in: Am J Surg Pathol 2004 May;28(5):following table of contents
25. Zembowicz A., Knoepp S.M., Bei T., et al. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol 31 11 (2007) 1764-1775
26. Donato R. S-100 proteins. Cell Calcium 7 3 (1986) 123-145
27. Baumal R., Kahn H.J., and Marks A. Role of antibody to S100 protein I diagnostic pathology. Lab Invest 59 1 (1988) 152-154
28. Argenyi Z.B., Cain C., Bromley C., et al. S-100 protein-negative malignant melanoma: fact or fiction? A light microscopic and immunohistochemical study. Am J Dermatopathol 16 (1994) 233-240
29. Marincola F.M., Hijazi Y.M., Fetsch P., et al. Analysis of expression of the melanoma associated antigens Mart-1 and gp-100 in metastatic melanoma cell lines and in situ lesions. J Immunother Emphasis Tumor Immunol 19 3 (1996) 192-205
30. Fetsch P.A., Marincola F.M., Filie A., et al. A Melanoma-associated antigen recognized by T cells (MART-1). Cancer 87 1 (1999) 37-42
31. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 45 12 (1980) 3012-3017
32. Azzola M.F., Shaw H.M., Thompson J.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97 (2003) 1488-1498
33. Kesmodel S.B., Karakousis G.C., Botbyl J.D., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12 6 (2005) 449-458 Epub 2005 Apr 19
34. Gimotty P.A., Guerry D., Ming M.E., et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22 (2004) 3668-3676
35. Gimotty P.A., Van Belle P., Elder D.E., et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23 31 (2005) 8048-8056
36. Ronan S.G., Eng A.M., Briele H.A., et al. Thin melanomas with regression and metastases. Arch Dermatol 123 10 (1987) 1326-1330
37. Clemente C.G., Mihm Jr. M.C., Bufalino R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 7 (1996) 1303-1310
38. Soifer R., Hodi F.S., Haluska F., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21 17 (2003) 3343-3350
39. Hodi F.S., Oble D.A., Drappatz J., et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5 9 (2008) 557-561
40. Harrist T.J., Rigel D.S., Day Jr. C.L., et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53 10 (1984) 2183-2187
41. Day Jr. C.L., Harrist T.J., Gorstein F., et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 194 1 (1981) 108-112
42. Barnhill R.L., and Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology 36 5 (2004) 485-490
43. Barnhill R., Dy K., and Lugassy C. Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis. J Invest Dermatol 119 3 (2002) 705-706
44. Dadras S.S., Lange-Asschenfeldt B., Velasco P., et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 18 9 (2005) 1232-1242
45. Morton D.L., and Cochran A.J. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 151 2 (2004) 308-319
46. Morton D.L. Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 66 4 (1997) 267-269
47. Cochran A.J., Morton D.L., Stern S., et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14 6 (2001) 604-608
48. Cochran A.J., Huang R.R., Lee J., et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6 9 (2006) 659-670
49. Cochran A.J., Wen D.R., Huang R.R., et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17 7 (2004) 747-755
50. van Akkooi A.C., Nowecki Z.I., Voit C., et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248 6 (2008) 949-955
51. van Akkooi A.C., de Wilt J.H., Verhoef C., et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 17 10 (2006) 1578-1585